ImmunityBio, Inc. (IBRX): Total Liabilities
$1.00B
As of 2025-12-31
$1.67B
As of 2026-06-30
+7.2%
3-year compound annual growth
+24.1%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.00B | +15.0% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $871.06M | -20.1% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $1.09B | +34.3% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $812.18M | +13.9% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $712.82M | +109.7% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $339.87M | n/m | 2022-03-01, Balance as of period end |
| 2019-12-31 | $22.44M | -37.6% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $35.94M | +13.8% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $31.60M | +31.2% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $24.08M | +121.8% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $10.85M | n/a | 2017-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $611.11M | -7.6% |
Compare IBRX, IPSC, ATRA, GLUE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗